News und Analysen
Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
Savara Announces Proposed Public Offering of Common Stock
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public
Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2020 and
Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the expansion of a
BOIRON : 2020 results
The Board of Directors of BOIRON, at its meeting on March 10, 2021 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31
Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector
Waters Corporation (NYSE:WAT) today released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight (TOF) mass spectrometer (MS) for small molecule analysis for
GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer
Agilent Technologies Inc. (NYSE: A), today announced that Dr. Katharine (Kate) Knobil is joining Agilent as the company’s chief medical officer (CMO). The chief medical officer at Agilent is a
THERANEXUS EXTENDS THE CAPABILITIES OF NEUROLEAD, ITS ACTIVE AGENT SCREENING PLATFORM, TO AUTOPHAGY AND NEUROLOGICAL LYSOSOMAL STORAGE DISORDERS
Lyon, 9 March 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
ICON plc to Present at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
Simulations Plus to Present at Oppenheimer Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn
Charles River Laboratories Prices $1 Billion of Senior Notes
Charles River Laboratories International, Inc. (NYSE: CRL) announced that on March 8, 2021 it priced its private offering (the “offering”) of $500 million in aggregate principal amount of 3.750%
PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations
PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX®
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec
Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection
Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in
VALBIOTIS wird Ergebnisse zu TOTUM-854 bei arterieller Hypertonie auf der Jahrestagung der Europäischen Gesellschaft für Hypertonie (ESH) und der Internationalen Gesellschaft für Hypertonie (ISH) im April 2021 vorstellen
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / qualifiziert für PEA/SME), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
VALBIOTIS Selected to Present TOTUM-854’s Results on Arterial Hypertension at the Annual Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) in April 2021
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL, eligible for PEA / SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic
Charles River Laboratories Announces Planned Offering of $1 Billion of Senior Notes
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $1 billion aggregate principal amount of senior notes due 2029 and 2031 (the “notes”) in an
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Barclays Global Healthcare Conference on Wednesday, March 10th, at 10:20 a.m. ET
IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17, 2021
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/
Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq
Neue Studie zeigt auf, dass mehr Auftragsforschungsinstitute Maßnahmen ergreifen, um dem dringenden Bedarf an schnelleren klinischen Studien gerecht zu werden
Auftragsforschungsinstitute machen bedeutende Fortschritte bei der Modernisierung und Verkürzung klinischer Studien, so die Ergebnisse der aktuellen Veeva Unified Clinical Operations Survey: Annual
QIAGEN Announces 20-F Annual Report Filing for 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended
Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
Illumina, Inc.’s (NASDAQ: ILMN) NextSeq™ 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq™Dx which was approved previously